KPV

Overview

KPV is a tripeptide consisting of the amino acids lysine-proline-valine (Lys-Pro-Val), corresponding to residues 11-13 at the C-terminal end of alpha-melanocyte-stimulating hormone (alpha-MSH). Alpha-MSH is a 13-amino-acid neuropeptide produced by the pituitary gland and various peripheral tissues, long recognized for its role in pigmentation, energy homeostasis, and — critically for KPV's relevance — anti-inflammatory signaling.

The discovery that alpha-MSH's anti-inflammatory activity could be largely attributed to its C-terminal tripeptide fragment was a significant finding in melanocortin research. Work by Lipton, Catania, and colleagues throughout the 1990s and 2000s demonstrated that KPV retains the anti-inflammatory properties of the full alpha-MSH molecule without its melanogenic (pigmentation-inducing) effects. This dissociation of anti-inflammatory activity from pigmentation effects made KPV an attractive research target.

KPV has garnered particular attention in the context of gastrointestinal inflammation. Its small size (three amino acids) gives it favorable characteristics for mucosal absorption, and it has demonstrated activity in multiple preclinical models of colitis and intestinal inflammation. As of 2026, KPV remains a research compound with no approved clinical indications, though its preclinical profile continues to generate interest in inflammatory bowel disease research.

Structure and Sequence

KPV is among the smallest biologically active peptides studied in the inflammatory research space:

Sequence: Lys-Pro-Val (K-P-V)

• Molecular formula: C₁₆H₃₀N₄O₄
• Molecular weight: 342.43 g/mol
• Origin: C-terminal fragment (residues 11-13) of alpha-MSH
• Parent peptide: Alpha-MSH (Ac-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH₂)

The proline residue at position 2 confers conformational rigidity to the peptide backbone, which may contribute to its resistance to enzymatic degradation relative to other tripeptides. The compact size of KPV is notable — most bioactive peptides require significantly longer sequences to maintain biological activity.

Mechanism of Action

NF-kB Pathway Inhibition

The primary mechanism through which KPV exerts anti-inflammatory effects is inhibition of the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB) signaling pathway. NF-kB is a master transcription factor that regulates the expression of hundreds of pro-inflammatory genes, including those encoding cytokines (TNF-alpha, IL-1beta, IL-6, IL-8), adhesion molecules, and inducible enzymes (iNOS, COX-2).

KPV has been shown to:

• Inhibit IkB-alpha phosphorylation and degradation, preventing NF-kB nuclear translocation
• Reduce NF-kB DNA-binding activity in activated immune cells
• Decrease downstream production of pro-inflammatory cytokines including TNF-alpha and IL-8

Melanocortin Receptor Interactions

While the full alpha-MSH molecule signals primarily through melanocortin receptors (MC1R through MC5R), KPV's receptor interactions are more nuanced. Some studies suggest KPV may interact with MC1R at high concentrations, but accumulating evidence indicates that a significant portion of KPV's anti-inflammatory effects may occur through receptor-independent mechanisms — specifically, direct intracellular entry and NF-kB pathway modulation.

Research by Kannengiesser et al. (2008) demonstrated that KPV can enter colonocytes and immune cells, potentially through peptide transporters such as PepT1, and exert its anti-inflammatory effects from within the cell rather than through classical membrane receptor signaling.

Inflammasome Modulation

Emerging research suggests KPV may also modulate NLRP3 inflammasome activation, a multiprotein complex responsible for processing and releasing IL-1beta and IL-18. This represents an additional anti-inflammatory mechanism beyond NF-kB inhibition.

Direct Antimicrobial Properties

Like its parent molecule alpha-MSH, KPV has demonstrated modest antimicrobial activity against certain bacterial strains, including Staphylococcus aureus and Candida albicans. This dual anti-inflammatory and antimicrobial profile is relevant to its potential applications in mucosal immunity, where microbial and inflammatory pathways intersect.

Research Summary

Area of Study	Key Finding	Notable Reference
Colitis (DSS model)	Oral KPV reduced colonic inflammation scores and weight loss in dextran sulfate sodium-induced colitis in mice	Dalmasso et al., PLoS ONE, 2008
NF-kB inhibition	KPV inhibited NF-kB activation in human intestinal epithelial cells and macrophages	Brzoska et al., Annals of the New York Academy of Sciences, 2003
Nanoparticle delivery	KPV-loaded nanoparticles targeted to inflamed colonic tissue showed enhanced efficacy in murine colitis	Xiao et al., Biomaterials, 2017
Inflammatory cytokines	Reduced TNF-alpha, IL-8, and nitric oxide production in activated human monocytes	Luger et al., Annals of the New York Academy of Sciences, 1999
PepT1 transport	KPV enters colonocytes via PepT1 transporter to exert intracellular anti-inflammatory effects	Kannengiesser et al., Journal of Cellular Physiology, 2008
Wound healing (skin)	Alpha-MSH peptides including KPV accelerated re-epithelialization in dermal wound models	Brzoska et al., Endocrine Reviews, 2008
Antimicrobial activity	Demonstrated candidacidal and bactericidal activity at micromolar concentrations	Cutuli et al., Peptides, 2000
Inflammatory bowel review	Comprehensive review of melanocortin peptides in IBD confirmed KPV as lead candidate fragment	Dalmasso et al., Peptides, 2013
Nanoparticle oral delivery	Hyaluronic acid-functionalized polymeric nanoparticles improved oral KPV delivery to inflamed colon	Xiao et al., Molecular Therapy, 2016

Pharmacokinetics

Formal pharmacokinetic studies specific to KPV are limited compared to more extensively characterized peptides. Available data indicates:

• Half-life: Estimated to be very short in plasma (minutes), consistent with tripeptide metabolism. However, intracellular accumulation via PepT1 transport may extend the effective duration of action at target tissues
• Oral bioavailability: KPV's small size and proline-mediated structural stability suggest oral activity, supported by efficacy in oral dosing studies in murine colitis models. The PepT1 transporter in intestinal epithelium facilitates absorption
• Metabolism: Subject to rapid proteolytic degradation in plasma by aminopeptidases and dipeptidylpeptidases. The intracellular route of action may partially circumvent this limitation
• Tissue targeting: Nanoparticle formulations have been developed to improve colonic targeting and extend residence time at inflamed mucosal surfaces

The development of nanoparticle delivery systems for KPV (notably hyaluronic acid-coated PLGA nanoparticles) represents an active area of formulation research aimed at overcoming the pharmacokinetic limitations inherent to tripeptide therapeutics.

Dosing Protocols

The following dosing information is compiled from published research and community discussion for educational purposes only. No FDA-approved human dosing guidelines exist for research peptides. Always consult a qualified healthcare professional.

Subcutaneous Protocol

Phase	Daily Dose	Frequency	Duration
Standard	200–500 mcg	Once daily	4–6 weeks
Off period	—	—	2–4 weeks

Oral Protocol (GI-Specific)

Phase	Daily Dose	Frequency	Duration
Standard	200–500 mcg	Once daily	4–6 weeks

Key Points

• Routes: Subcutaneous injection (systemic) or oral (GI-targeted — KPV enters colonocytes via PepT1 transporter)
• Cycle length: 4–6 weeks on, 2–4 weeks off
• Injection timing: Once daily, morning
• Oral timing: Once daily on empty stomach for gut-specific applications
• Often discussed alongside: BPC-157 for complementary gut-healing protocols

Reconstitution (5 mg vial)

• Add 2.0 mL bacteriostatic water → 2.5 mg/mL concentration
• At this concentration: 1 unit = 25 mcg on a U-100 insulin syringe
• 500 mcg = 20 units

Dosing Protocols

The following dosing information is compiled from published research and community discussion for educational purposes only. No FDA-approved human dosing guidelines exist for most research peptides. Always consult a qualified healthcare professional.

Reconstitution

Parameter	Value
Vial size	10 mg
Bacteriostatic water	3.0 mL
Concentration	~3,333 mcg/mL
Storage (reconstituted)	2-8 °C, use within ~30 days
Storage (lyophilized)	-20 °C

Dosing Schedule

Phase	Dose	Frequency	Syringe units	Duration
Starting	200 mcg	Once daily	6 units	Week 1
Titration	300 mcg	Once daily	9 units	Week 2
Mid-range	400 mcg	Once daily	12 units	Week 3
Target	500 mcg	Once daily	15 units	Weeks 4-8+

Cycle Guidelines

• Cycle length: 8-12 weeks (up to 16 weeks)
• Route: Subcutaneous injection
• Timing: Consistent daily timing
• Injection sites: Rotate between abdomen, thighs, and upper arms (at least 1-2 inches apart)

Common Discussion Topics

1. Gut inflammation and IBD — KPV is most frequently discussed in the context of inflammatory bowel disease, ulcerative colitis, and general intestinal inflammation due to its NF-kB inhibitory effects in colonic tissue
2. Oral administration — The peptide's activity when taken orally distinguishes it from most peptides that require injection, making it a subject of interest for oral peptide delivery research
3. Comparison with BPC-157 — Often compared with BPC-157 for gut-related applications; KPV is discussed as more specifically anti-inflammatory while BPC-157 is considered more broadly reparative
4. Nanoparticle formulations — Growing interest in targeted delivery systems that could enhance KPV's efficacy at inflamed intestinal sites
5. Alpha-MSH fragment activity — KPV's ability to retain anti-inflammatory effects without melanogenic activity is discussed as evidence for the dissociability of alpha-MSH's diverse biological roles
6. Stacking protocols — Community discussions frequently pair KPV with other gut-supportive compounds including BPC-157 and various probiotic formulations

Limitations of Current Research

1. Predominantly preclinical data — No completed human clinical trials specific to KPV have been published
2. Limited pharmacokinetic characterization — Formal PK studies in humans are absent
3. Delivery challenges — As a tripeptide, KPV is subject to rapid degradation, and effective delivery remains a formulation challenge
4. Mechanism overlap — The relative contributions of receptor-dependent versus receptor-independent mechanisms remain to be fully delineated

Related Compounds

• BPC-157 — a pentadecapeptide with complementary gut-protective and tissue-repair properties
• LL-37 — a cathelicidin antimicrobial peptide with immunomodulatory activity at mucosal surfaces
• Thymosin Alpha-1 — an immune-modulating peptide with anti-inflammatory research applications
• Alpha-MSH — the full parent hormone from which KPV is derived
• Melanotan II — a synthetic melanocortin receptor agonist acting on the same receptor family